Donate to Illuminate Order Brochures Contact TSF
Facebook Logo Twitter Logo Youtube Logo Instagram Logo LinkedIn Logo TikTok Logo Blue Sky Logo

Archives: Research Summaries

Real-Life Evaluation of the MOGAD Diagnostic Criteria

Real-Life Evaluation of the MOGAD Diagnostic Criteria

Journal: Neurology Neuroimmunology & Neuroinflammation; August 19, 2025

Author(s): Sara Carta, Elia Sechi Alessandro Dinoto, Chiara Mancinelli, Giacomo Greco, Giorgia Teresa Maniscalco Sara Cornacchini, Maria Pia Giannoccaro, Francesca Calabria, Alessandro Marziali, Stefano Masciocchi, Mario Risi, Alberto Cossu, Irene Volonghi, Gaetano Cantalupo, Marco Zoccarato, Riccardo Orlandi, Elisabetta Del Zotto, Diana Ferraro, Milena Trentinaglia, Stefano De Biase, Luisa Grazian, Francesca Caleri, Maria Rachele Bianchi, Patrizia Rossi, Eleonora Virgilio, Marco Capobianco, Rosa Cortese, Carla Tortorella, Francesca Rossi, Giovanna De Luca, Anna Perelli, Silvia Bozzetti, Luigi Zuliani, Margherita Nosadini, Stefano Sartori, Laura Brambilla, Alberto Gajofatto, Alberto Vogrig, Luca Massacesi, Valentina Damato, Matteo Gastaldi, and Sara Mariotto

How well do the new diagnostic criteria for MOGAD work in real-life clinical practice? Results from multi-center study in Italy


Consensus Recommendations for the Diagnosis and Treatment of Neuromyelitis Optica Spectrum Disorders (NMOSD): The MENACTRIMS Guidelines

Consensus Recommendations for the Diagnosis and Treatment of Neuromyelitis Optica Spectrum Disorders (NMOSD): The MENACTRIMS Guidelines

Journal: CNS Drugs; January 27, 2026

Author(s): Bassem Yamout, Riadh Gouider, Raed Al-Roughani, Salman Aljarallah, Nevine Shalaby, Jaber Al-Khabouri, Anu Jacob, Jihad Inshasi, Akram Mahdawi, Ahmed Shatila, Maya Zeineddine, Sarmad Al-Mashetah, Beatrice Canibano, Saeed Bohlega, Fatema Abdulla, Ilham Slassi, Aly Hassan, Sandra Ahmed, Magd Zakaria, Mohammed AlJumah, Yaser Al-Malik

How should NMOSD be diagnosed and treated in clinical practice? Guidelines for the Middle East and North Africa region


Long-Term Efficacy and Safety of Satralizumab in Patients With Neuromyelitis Optica Spectrum Disorder From the SAkuraMoon Open-Label Extension Study

Long-Term Efficacy and Safety of Satralizumab in Patients With Neuromyelitis Optica Spectrum Disorder From the SAkuraMoon Open-Label Extension Study

Journal: Neurology; July 30, 2025

Author(s): Jeffrey L Bennett, Kazuo Fujihara, Albert Saiz, Anthony L Traboulsee, Benjamin M Greenberg, Brian G Weinshenker, Francesco Patti, Ingo Kleiter, Jacqueline Palace, Jerome De Seze, Rachael Evans, Kathleen Blondeau, Gaëlle Klingelschmitt, Ivana Vodopivec, Masouda Rahim, Takashi Yamamura

How safe and effective is satralizumab over the long term in people with NMOSD?


Neuropsychologic Impact of MOGAD: A Patient Reported Outcomes Study

Neuropsychologic Impact of MOGAD: A Patient Reported Outcomes Study

Journal: Neurology; October 8, 2024

Author(s): Bruna Leles Vieira de Souza, Yihan Zhang, Rebecca Salky, Monique Anderson, Takahisa Mikami, Rebecca Gillani, Mattia Wruble, Gabriela Romanow, Anastasia Vishnevetsky, and Giovanna Manzano

How do MOGAD patients report their own quality of life?


The real-world applicability of the 2023 international myelin oligodendrocyte glycoprotein antibody-associated disease criteria in a Latin American cohort

The real-world applicability of the 2023 international myelin oligodendrocyte glycoprotein antibody-associated disease criteria in a Latin American cohort

Journal: European Journal of Neurology; September 17, 2024

Author(s): Edgar Carnero Contentti, Claudia Pestchanker, Ethel Ciampi, Sheila Castro Suarez, Cesar Caparo Zamalloa, Vanesa Daccach Marques, Katharina Messias, José Ignacio Gortari, Verónica Tkachuk, Berenice Silva, Carolina Mainella, Saúl Reyes, Jaime Toro, Juan Rodriguez, Edgar Correa-Diaz, Juan I. Rojas, Friedemann Paul

Evaluating the 2023 diagnostic criteria for MOGAD in real-world settings in Latin America


Time to Treat First Acute Attack of Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease

Time to Treat First Acute Attack of Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease

Journal: JAMA Neurology; September 3, 2024

Author(s): Young Nam Kwon, Boram Kim, Jun-Soon Kim, Kyung Seok Park, Da-Young Seo, Hyunjin Kim, Eun-Jae Lee, Young-Min Lim, Hyunjin Ju, Yeon Hak Chung, Ju-Hong Min, Tai-Seung Nam, Sooyoung Kim, Eunhee Sohn, Kyong Jin Shin, Jin Myoung Seok, Sunyoung Kim, Jong Seok Bae, Sukyoon Lee, Seong-il Oh, Yu Jin Jung, Jinseok Park, Seung Hyun Kim, Ki Hoon Kim, Ho Jin Kim, Jae Ho Jung, Seong-Joon Kim, Seung Woo Kim, Myoung-jin Jang, Jung-Joon Sung, Patrick Waters, Ha Young Shin, Sung-Min Kim

Does time taken to treat the first MOGAD attack affect the disease course? A study from South Korea


Industry Partners

Community Partners